132 related articles for article (PubMed ID: 34635426)
1. Antimicrobial treatment of monomicrobial phenotypic carbapenem-resistant Klebsiella pneumoniae bacteremia: Two are better than one.
Tsai WC; Syue LS; Ko WC; Lo CL; Lee NY
J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 2):1219-1228. PubMed ID: 34635426
[TBL] [Abstract][Full Text] [Related]
2. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia.
Lee NY; Lo CL; Chen PL; Syue LS; Li CW; Li MC; Ko WC
Int J Antimicrob Agents; 2021 Feb; 57(2):106250. PubMed ID: 33264671
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Seo H; Lee SC; Chung H; Ra SH; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Woo JH; Chong YP
Int J Antimicrob Agents; 2020 Oct; 56(4):106126. PubMed ID: 32755654
[TBL] [Abstract][Full Text] [Related]
5. Multicenter Genomic Analysis of Carbapenem-Resistant Klebsiella pneumoniae from Bacteremia in China.
Cienfuegos-Gallet AV; Zhou Y; Ai W; Kreiswirth BN; Yu F; Chen L
Microbiol Spectr; 2022 Apr; 10(2):e0229021. PubMed ID: 35230130
[TBL] [Abstract][Full Text] [Related]
6. Colistin versus polymyxin B for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Vieceli T; Henrique LR; Rech TH; Zavascki AP
J Infect Chemother; 2024 Jul; 30(7):621-625. PubMed ID: 38244722
[TBL] [Abstract][Full Text] [Related]
7. Carbapenem-resistant Klebsiella pneumoniae bloodstream infections in haematological malignances and hematopoietic stem cell transplantation: Clinical impact of combination therapy in a 10-year Brazilian cohort.
de Souza ILA; Cappellano P; Ferreira DB; Bergamasco MD; das Chagas Neto TC; Kerbauy FR; Baiocchi OCG; Pignatari ACC
PLoS One; 2024; 19(1):e0297161. PubMed ID: 38277372
[TBL] [Abstract][Full Text] [Related]
8. Risk factors and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae bacteraemia in children: a retrospective study.
Meng H; Yang J; Niu M; Zhu H; Zhou Y; Lu J
Int J Antimicrob Agents; 2023 Oct; 62(4):106933. PubMed ID: 37500022
[TBL] [Abstract][Full Text] [Related]
9. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.
Xiao T; Zhu Y; Zhang S; Wang Y; Shen P; Zhou Y; Yu X; Xiao Y
J Infect Dis; 2020 Mar; 221(Suppl 2):S174-S183. PubMed ID: 32176799
[TBL] [Abstract][Full Text] [Related]
10. A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.
Aslan AT; Kırbaş E; Sancak B; Tanrıverdi ES; Otlu B; Gürsoy NC; Yılmaz YA; Tozluyurt A; Liste Ü; Bıçakcıgil A; Hazırolan G; Dağ O; Güven GS; Akova M;
Int J Antimicrob Agents; 2022 Apr; 59(4):106554. PubMed ID: 35176476
[TBL] [Abstract][Full Text] [Related]
11. Mortality-related factors in patients with OXA-48 carbapenemase-producing Klebsiella pneumoniae bacteremia.
Rodríguez OL; Sousa A; Pérez-Rodríguez MT; Martínez-Lamas L; Suárez RL; Martínez CT; Pino CP; Vidal FV; Pérez-Landeiro A; Casal MC
Medicine (Baltimore); 2021 Apr; 100(14):e24880. PubMed ID: 33832068
[TBL] [Abstract][Full Text] [Related]
12. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Lo CL; Lee CC; Li CW; Li MC; Hsueh PR; Lee NY; Ko WC
J Microbiol Immunol Infect; 2017 Jun; 50(3):355-361. PubMed ID: 26423244
[TBL] [Abstract][Full Text] [Related]
13. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.
Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M;
Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283
[TBL] [Abstract][Full Text] [Related]
14. Cefoxitin versus carbapenems as definitive treatment for extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteremia in intensive care unit: a propensity-matched retrospective analysis.
Dequidt T; Bastian S; Nacher M; Breurec S; Carles M; Thiery G; Camous L; Tressieres B; Valette M; Pommier JD
Crit Care; 2023 Nov; 27(1):418. PubMed ID: 37915017
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan.
Su CF; Chuang C; Lin YT; Chan YJ; Lin JC; Lu PL; Huang CT; Wang JT; Chuang YC; Siu LK; Fung CP
Eur J Clin Microbiol Infect Dis; 2018 Apr; 37(4):651-659. PubMed ID: 29238934
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study.
Wang M; Earley M; Chen L; Hanson BM; Yu Y; Liu Z; Salcedo S; Cober E; Li L; Kanj SS; Gao H; Munita JM; Ordoñez K; Weston G; Satlin MJ; Valderrama-Beltrán SL; Marimuthu K; Stryjewski ME; Komarow L; Luterbach C; Marshall SH; Rudin SD; Manca C; Paterson DL; Reyes J; Villegas MV; Evans S; Hill C; Arias R; Baum K; Fries BC; Doi Y; Patel R; Kreiswirth BN; Bonomo RA; Chambers HF; Fowler VG; Arias CA; van Duin D;
Lancet Infect Dis; 2022 Mar; 22(3):401-412. PubMed ID: 34767753
[TBL] [Abstract][Full Text] [Related]
17. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
Ko JH; Lee NR; Joo EJ; Moon SY; Choi JK; Park DA; Peck KR
Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
[TBL] [Abstract][Full Text] [Related]
18. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.
Hussein K; Raz-Pasteur A; Finkelstein R; Neuberger A; Shachor-Meyouhas Y; Oren I; Kassis I
J Hosp Infect; 2013 Apr; 83(4):307-13. PubMed ID: 23313086
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for infection and mortality caused by carbapenem-resistant Klebsiella pneumoniae: A large multicentre case-control and cohort study.
Lou T; Du X; Zhang P; Shi Q; Han X; Lan P; Yan R; Hu H; Wang Y; Wu X; Jiang Y; Yu Y
J Infect; 2022 May; 84(5):637-647. PubMed ID: 35301013
[TBL] [Abstract][Full Text] [Related]
20. Healthcare-associated carbapenem-resistant Klebsiella pneumoniae bloodstream infections: Risk factors, mortality, and antimicrobial susceptibility, 2017-2019.
Hsu JY; Chuang YC; Wang JT; Chen YC; Hsieh SM
J Formos Med Assoc; 2021 Nov; 120(11):1994-2002. PubMed ID: 33962811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
